A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
NCT04151563 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL
Last updated 2023-12-19
Summary
This study is for participants with Non-small Cell Lung Cancer that has spread or has reoccurred after failure of Chemotherapy and Immunotherapy
Conditions
- Carcinoma, Non-small Cell Lung Cancer
Interventions
- BIOLOGICAL
-
Specified dose on Specified days
- BIOLOGICAL
-
Specified dose on Specified days
- DRUG
-
Specified dose on Specified days
- BIOLOGICAL
-
Specified dose on Specified days
- BIOLOGICAL
-
Specified dose on Specified days
- DRUG
-
lucitanib
Specified dose on Specified days
Sponsors & Collaborators
-
Clovis Oncology, Inc.
collaborator INDUSTRY - collaborator INDUSTRY
- collaborator INDUSTRY
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-04-15
- Primary Completion
- 2023-12-17
- Completion
- 2026-05-13
- FDA Drug
- Yes
Countries
- United States
- Argentina
- Belgium
- Denmark
- Greece
- Mexico
- Netherlands
- Norway
- Poland
- Romania
Study Locations
More Related Trials
-
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
NCT01721759 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT06946797 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC
NCT04023617 ·Status: UNKNOWN ·Phase: PHASE2
-
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
NCT02846792 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
NCT03527108 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
NCT02477826 ·Status: COMPLETED ·Phase: PHASE3
-
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
NCT04310007 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
NCT02041533 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen
NCT02066636 ·Status: COMPLETED ·Phase: PHASE3
-
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
NCT03256136 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02574078 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
NCT03366766 ·Status: TERMINATED ·Phase: PHASE2
-
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
NCT03048136 ·Status: WITHDRAWN ·Phase: PHASE3
-
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT03417037 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
NCT03215706 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
NCT01454102 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
NCT03406715 ·Status: TERMINATED ·Phase: PHASE2
-
An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT03001882 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC
NCT07141563 ·Status: COMPLETED
-
Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer
NCT03121417 ·Status: WITHDRAWN ·Phase: PHASE2
-
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
NCT03041181 ·Status: TERMINATED ·Phase: PHASE2
-
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT00946712 ·Status: TERMINATED ·Phase: PHASE3
-
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
NCT02434081 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
NCT07083375 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
NCT02409368 ·Status: COMPLETED ·Phase: PHASE2